Form 4: Moderna Director David Rubenstein Exercises RSU Award

Moderna, Inc. Director David M. Rubenstein acquired 8,116 shares of common stock through the vesting of restricted stock units.

Summary

• Director David M. Rubenstein acquired 8,116 shares of Moderna, Inc. (MRNA) common stock on April 30, 2026.
• The acquisition resulted from the full vesting of a restricted stock unit (RSU) award.
• Following the transaction, the reporting person holds 9,643 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting standard compensation vesting rather than a strategic market signal.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard component of executive and board compensation packages in the biotechnology sector, typically having no material impact on market sentiment.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation in large-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity compensation vesting.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, David Rubenstein, Equity Compensation